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De novo posttransplant donor-specific HLA-antibody (dnDSA) detection is now recognized as a tool to identify patients at risk for
antibody-mediated rejection (AMR) and graft loss. It is still unclear whether the time interval from transplant to DSA occurrence
influences graft damage. Utilizing sera collected longitudinally, we evaluated 114 consecutive primary pediatric kidney recipients
grafted between 2002 and 2013 for dnDSA occurrence by Luminex platform. dnDSAs occurred in 39 patients at a median time
of 24.6 months. In 15 patients, dnDSAs developed within 1 year (early-onset group), while the other 24 seroconverted after the
first posttransplant year (late-onset group). The two groups were comparable when considering patient- and transplant-related
factors, as well as DSA biological properties, including C1q and C3d complement-binding ability. Only recipient age at transplant
significantly differed in the two cohorts, with younger patients showing earlier dnDSA development. Late AMR was diagnosed in
47% of the early group and in 58% of the late group. Graft loss occurred in 3/15 (20%) and 4/24 (17%) patients in early- and late-onset
groups, respectively (𝑝 = ns). In our pediatric kidney recipients, dnDSAs predict AMR and graft loss irrespective of the time elapsed
between transplantation and antibody occurrence.
1. Introduction
Humoral alloimmunity leading to chronic antibody-
mediated rejection (AMR) has been recognized as a major
obstacle to long-term kidney graft (KTx) survival [1–5].
In addition to sensitized patients who suffer from poorer
kidney graft outcome due to a higher incidence of AMR,
a number of pretransplant HLA-antibody-negative kidney
recipients, usually considered at low immunological risk, will
also develop chronic allograft dysfunction and, ultimately,
graft loss [6–16]. A positive association between the presence
of de novo posttransplant donor-specific HLA antibodies
(dnDSAs) after transplantation and poor transplant outcome
has been demonstrated also in this patient category.
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This observation has prompted recommendations on
posttransplant HLA-antibody monitoring as a tool to
identify patients at risk for antibody-mediated rejection and
graft loss [6–16].
It has also been shown that DSA development continues
as an active process evenmany years after transplantation [12,
14–17], and although DSAs may be detected also in patients
with long-term functioning allografts, persistent kidney loss
due to antibody-mediated injury is observed throughout the
whole posttransplant period [5]. Time to DSA development
has been suggested as a variable that could impact transplant
outcome, with early-onset DSAs being associated with lower
graft survival [7], but data on this clinical scenario are not
conclusive [9, 17].
We conducted a longitudinal analysis on a pediatric
cohort of pretransplant HLA-antibody-negative, first kidney
recipients sequentially monitored for posttransplant DSA
onset and alloantibody biological properties, in order to
evaluate whether the timing of dnDSA appearance could
influence AMR development and graft outcome.
2. Patients and Methods
2.1. Patients. Between July 2002 and March 2013, 125 con-
secutive patients were referred to the Genoa Pediatric Kid-
ney Transplant Program for first allografting. Pretransplant
patient sera were screened periodically for the presence of
panel reactive anti-HLA antibodies by complement depen-
dent cytotoxicity technique and by a bead-based assay [12].
All grafts were performed after a negative T cell cross-
match. Our standard of care for low immunological risk
kidney transplant patients consisted of induction with basil-
iximab and a triple drug immunosuppressive regimen includ-
ing a calcineurin inhibitor (cyclosporin A or tacrolimus),
mycophenolatemofetil, and prednisone. Biopsy-proven acute
cellular rejection episodes were treated with pulse intra-
venous methylprednisolone. Patients developing late AMR,
as evidenced by circulating HLA DSAs and histological
features of antibody-mediated tissue and vascular injuries,
were treated with a protocol including a combination of
plasmaphereses, i.v. human Ig, and anti-CD20 monoclonal
antibody. Graft function was estimated by calculating eGFR
using the Schwartz [18] or MDRD [19] formula, when
appropriate.
Graft biopsies were performed for clinical indication
(graft function decline and/or proteinuria); since 2010, DSA
positivity was also included among indications. Rejections
were histologically graded following the Banff 97 criteria with
updates. Banff 2009 and Banff 2013 criteria were employed
for classifying C4d positive and negative AMR [20, 21]. All
biopsies performed before 2014 were regraded according to
the Banff 2013 criteria. C4d staining was performed on frozen
sections by indirect immunofluorescence.
This study was approved by the Institutional Review
Board of the Fondazione Ca’ Granda, Ospedale Maggiore
Policlinico, Milano (867/2014).
2.2.Detection andCharacterization ofHLAAntibodies. Recip-
ients of first graft who were found positive for the pres-
ence of anti-HLA antibodies in current and/or historical
pretransplant sera (𝑛 = 11) were not included, resulting in
a total of 114 nonsensitized first kidney allograft pediatric
recipients monitored for dnDSA (Table 1). Sera for HLA-
antibody monitoring were collected at transplantation, every
three months in the first posttransplant year and annually
thereafter. Samples obtained before 01/2010 belonged to a
unique source of sera analyzed retrospectively for HLA
antibodies, while from 02/2010 all samples were collected
and analyzed prospectively [12]. An average of >8 samples
per patient were analyzed. Complement-binding activity was
analyzed on sera collected at DSA appearance and at biopsy
or at follow-up.
HLA typing of kidney graft recipients and donors was
performed as previously described [22]. Anti-HLA class
I and class II IgG antibodies were tested with a bead-
based detection assay after serum EDTA treatment, to avoid
underestimation of antibody MFI strength [23–25]. We used
the LABScreen Mixed kit and the Single-Antigen Bead
(SAB) assays (One Lambda Inc., CA, USA) to identify
HLA class I and class II specificities [12, 22]. Screening
assay results above a cut-off value of 3.0 ratio between
the sample and negative control were considered positive.
Single-antigen results above a MFI cut-off value of 1.000
were considered positive. Heat inactivated patient sera were
tested with C1qScreen (One Lambda) for identification of
complement-binding antibodies, as described [26]. Antibody
positivity was assigned at >500 MFI. Serum samples were
analyzed in a blinded fashion for the presence of C3d-binding
DSAwith the single-antigen flow bead technology, according
to themanufacturer’s protocol (Immucor LifecodeTransplant
Diagnostics Nijlen, Belgium). Positivity was assigned as
previously detailed [27].
2.3. Statistical Analysis. Data were described as the mean
and standard deviation (SD) or median and range if contin-
uous and as count and percent if categorical. To determine
differences among patient groups, categorical variables were
compared by chi-squared analysis, continuous variables with
𝑡-tests, and, if skewed, nonparametric tests (Kruskal-Wallis
one-way analysis of variance, Mann–Whitney 𝑈 test). 𝑝
values < 0.05 were considered statistically significant. Event-
free survival was estimated with the Kaplan-Meier method
andwas compared between risk groupswith the log-rank test.
For graft failure, censoring event was death with functioning
graft. For AMR, censoring event was graft failure. Patients
who did not experience graft failure or AMRwere censored at
the end of the follow-up. Stata 13 (Stata Corporation, College
Station, TX, USA) or theNCSS System (NCSS, Cary, NC)was
used for computation.
3. Results
3.1. Clinical and Immunological Characteristics of the Patients
according to Time of dnDSA Development. The cohort
median follow-up was 6.7 years (range 2.0–12.6). Antibody
identification was based on longitudinal analysis of collected
sera in both retrospective and prospective sample series.
Among the 114 patients analyzed, 39 patients (34%) developed
dnDSAs at a median time of 24.6 months (range 3–115
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Table 2: Antibody characteristics in 39 de novo donor specific HLA antibody (dnDSA) positive patients.
Variables
All patients with
dnDSAs
(𝑛 = 39)
Patients with dnDSAs
occurring within year 1
(𝑛 = 15)
Patients with dnDSAs
occurring beyond year 1
(𝑛 = 24)
𝑝 value
dnDSA specificities, nr/patient∗ 1.97 ± 1.29 1.87 ± 1.25 2.04 ± 1.33 0.68
Persistent∗∗dnDSAs 35 (90%) 13 (87%) 22 (92%) 0.63
HLA class I dnDSAs 8 (21%) 2 (13%) 6 (25%) 0.45
HLA class II dnDSAs 18 (46%) 8 (53%) 10 (42%) 0.52
HLA class I and II dnDSAs 13 (33%) 5 (33%) 8 (33%) 1.00
HLA-A dnDSAs 16 (41%) 5 (33%) 11 (61%) 0.51
HLA-B dnDSAs 12 (31%) 3 (20%) 9 (37%) 0.30
HLA-C dnDSAs 7 (18%) 3 (20%) 4 (17%) 1.00
HLA-DR dnDSAs 6 (15%) 3 (20%) 3 (12%) 0.66
HLA-DQ dnDSAs 28 (72%) 11 (73%) 17 (71%) 1.00
HLA-DP dnDSAs 1 (3%) 0 1 (4%) 1.00
Immunodominant dnDSAs
MFI at onset∗ 9501 ± 7198 10483 ± 7020 8888 ± 7387 0.51
MFI at biopsy or peak∗ 12043 ± 7842 12061 ± 6683 12031 ± 8626 0.99
C1q positivityof dnDSAs
At dnDSA onset 25 (64%) 12 (80%) 13 (54%) 0.17
At biopsy or MFI peak 29 (74%) 12 (80%) 17 (71%) 0.71
C3d positivityof dnDSAs
At dnDSA onset 9 (23%) 3 (20%) 6 (25%) 1.00
At biopsy or MFI peak 16 (41%) 6 (40%) 10 (42%) 1.00
Percentages are calculated on the total number of patients from each group indicated at the top of the respective columns.
All data are reported as absolute numbers, unless otherwise specified; ∗data reported as mean ± sd.
∗∗DSA persistence was defined as positivity of the immunodominant DSA in all analyzed samples after first positivity.
MFI: mean fluorescence intensity.
months). The mean number of DSA specificities found per
patient was 1.97 (±1.29).
dnDSA-positive KTx recipients were stratified in two
groups, based on time to DSA appearance. We considered
patients with antibody occurrence within the first 12 months
(the period of greater immunosuppression reduction) as
those more prone to mount an immune response to the
graft (early-onset group, 𝑛 = 15) and patients with antibody
occurrence beyond the first posttransplant year as the late-
onset group (𝑛 = 24) (Table 1). The median time of DSA
appearance from transplantation was 9 months (range 3–12)
in the early group and 47 months (range 17–115) in the late
group. The two groups were comparable when considering
patient- and transplant-related factors, such as recipient
sex, living versus deceased donor graft source, cyclosporine
or tacrolimus administration, delayed graft function, 1-year
estimated glomerular filtration rate (eGFR), HLA class I and
II mismatches, and incidence of T cell mediated rejection
(TCMR) and late AMR. Only recipient age at transplant
was found to be significantly different in the two cohorts,
with younger patients showing earlier dnDSA development
(Table 1).
Patients belonging to the two groups did not display
any difference in all analyzed HLA-antibody characteris-
tics, including HLA class and locus specificity, persistence,
MFI, and C1q and C3d complement fraction binding ability
(Table 2). Antibodies detected in dnDSA-positive patients
recognized a total of 78 HLA antigen specificities. In the two
patient groups, HLA class I and class II specificities were
equally distributed, and a similar pattern was observed when
the analysis was carried out for each HLA antigen locus
(Table 3). As observed in the whole cohort, DQ dnDSAs were
the most represented antibodies in both groups. Regarding
DSA biological properties, such as MFI and C1q- and C3d-
binding ability, no significant differences were observed in
the two groups (Table 3). However, dnDSAs differed for
their complement-binding capability, as, with the exception
of HLA A2, all C3d-positive DSAs recognized HLA class
II and, in particular, DQ antigens, while C1q-positive DSAs
were homogeneously distributed between the two classes
(Figure 1). All C3d-binding DSAs were also found to bind
C1q.
3.2. Time to dnDSA Emergence and Correlation with AMR
and Clinical Outcome. AMR was diagnosed in 21 patients at
a median follow-up of 4.8 years from kidney transplantation
and was observed only in patients positive for dnDSAs
(Table 1). Considering BANFF 2013 criteria for classification
of AMR, 10 were acute active, and 11 were chronic active. The
distribution of acute active and chronic active AMR did not
Journal of Immunology Research 5
Table 3: Characteristics of 78 de novo donor specific HLA antibodies (dnDSAs) detected in 39 DSA positive kidney recipients.
Variables
Total number of
dnDSAs
(𝑛 = 78)
dnDSAs occurring within year
1
(𝑛 = 26)
dnDSAs occurring beyond
year 1
(𝑛 = 52)
𝑝 value
HLA class I dnDSAs 40 (51%) 11 (42%) 29 (56%) 0.34
HLA class II dnDSAs 38 (49%) 15 (58%) 23 (44%) 0.34
HLA class I dnDSAs, MFI∗ 4678 ± 4516 4838 ± 4717 4618 ±4521 0.89
HLA class II dnDSAs, MFI∗ 12033 ± 8410 10629 ± 7568 12949 ±8960 0.41
HLA-A 𝑑𝑛DSAs∗∗ 18 (23%) 5 (19%) 13 (25%) 0.78
HLA-B 𝑑𝑛DSAs∗∗ 15 (19%) 3 (11%) 12 (23%) 0.36
HLA-C dnDSAs 7 (9%) 3 (11%) 4 (7%) 0.68
HLA-DR 𝑑𝑛DSAs∗∗ 7 (9%) 4 (15%) 3 (6%) 0.21
HLA-DQ 𝑑𝑛DSAs∗∗ 30 (38%) 11 (42%) 19 (36%) 0.63
HLA-DP dnDSAs 1 (1%) 0 1 (2%) 1.00
C1q binding of dnDSAs 44 (56%) 17 (65%) 27 (52%) 0.33
HLA class I dnDSAs 20 (26%) 7 (27%) 13 (25%) 1.00
HLA class II dnDSAs 24 (31%) 10 (38%) 14 (27%) 0.31
C3d binding of dnDSAs 18 (23%) 7 (27%) 11 (21%) 0.58
HLA class I dnDSAs 1 (1%) 1 (4%) 0 0.33
HLA class II dnDSAs 17 (22%) 6 (23%) 11 (21%) 1.00
Percentages are calculated on the total number of antibodies from each group indicated at the top of the respective columns. All data are reported as absolute
numbers, unless otherwise specified.
∗Data reported as mean ± sd.
∗∗The number of antibodies detailed in this table is higher than that reported in Table 2, as some patients have multiple DSAs at this locus.
MFI: mean fluorescence intensity.
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Figure 1: HLA antigens recognized by C3d and/or C1q positive DSAs in the 39 dnDSA-positive patients. A total of 78 dnDSAs were identified
in the 39 kidney recipients. Of those, 44 bound C1q and 18 displayed binding ability for C3d.
differ between the early- and late-onset groups. To evaluate the
damaging effect of dnDSAs on the kidney graft, we analyzed
the rate of AMR-free survival from the time of DSA onset.
The interval from dnDSA development to AMRwas 2.5 years
(range 1.0–4.9) in the early-onset group, compared to 1.1 years
(range 0.1–4.6; 𝑝 = 0.08) in the late-onset group. AMR-free
survival did not differ between early- and late-onset groups
(Figure 2(a)).
The histological findings were investigated in graft
biopsies obtained from 30 out of 35 patients with per-
sistent dnDSAs (Figure 3); for the remaining 5 graft
recipients, no biopsies were available, as the patients
refused the procedure due to stable good allograft function.
The histological findings were analyzed both individually
(interstitial inflammation-i-, tubulitis-t-, ptc, glomerulitis-
g-, interstitial fibrosis-c-, tubular atrophy-ct-, transplant
6 Journal of Immunology Research
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Figure 2: Risk of developing late antibody-mediated rejection (AMR), renal function decline, and graft loss, in the 39 patients who developed
de novo donor-specific antibodies (dnDSAs), according to the time to HLA-antibody occurrence. (a) AMR-free allograft survival in kidney
graft recipients, stratified by early or late development of dnDSAs; (b) renal graft function decline (eGFR ≤ 50ml/min/1.73m2) in kidney
graft recipients, stratified by early or late development of dnDSAs; (c) allograft survival in kidney graft recipients, stratified by early or late
development of dnDSAs. The statistical difference between Kaplan-Meier survival curves was evaluated by the log-rank test and differences
with 𝑝 values < 0.05 were considered statistically significant.
glomerulopathy-cg-, chronic vascular changes-cv-, and inti-
mal arteritis-v-) and in functional clusters (ptc + g referring
to microcirculation inflammation, ptc + g + cg to microcircu-
lation lesions, i + t to tubulointerstitial inflammation, and ci
+ ct to tubulointerstitial scarring). No significant differences
were observed between the two groups (Figure 3).
We then evaluated the impact of early- versus late-onset
dnDSAs on graft loss. In the whole cohort of 114 patients,
9 grafts were lost, among which 7 grafts were lost due to
AMR and 2 to focal glomerulosclerosis recurrence.The latter
2 patients were dnDSAnegative. Among the 7 graft losses due
to AMR, 3 were observed in the early-onset group and 4 in
the late-onset dnDSA group. The median time interval from
dnDSA onset to graft loss was 4.0 years (range 3.5–5.0) in the
early-onset group, compared to 5.5 years (range 3.6–6.5) in the
late-onset group (𝑝 = ns) (Figure 2(c)). As the number of graft
losses in our cohort was limited, eGFR ≤ 50ml/min/1.73m2
was alternatively employed as an outcome end-point. Also in
this case, no difference was observed between the early-onset
and late-onset groups (Figure 2(b)).
4. Discussion
The problem of clarifying whether HLA antibodies develop-
ing at different posttransplant intervals could have different
cytotoxic capabilities and graft tissue damage potential has
Journal of Immunology Research 7
0
1
2
3
M
ea
n 
BA
N
FF
 sc
or
es
g i t v cg ci ct cv +
c
i
+
c
t
i
t
p
tc
C4
d
p
tc
+
g
p
tc
+
g
+
c
g
Figure 3: Histological analysis in 30 graft biopsies obtained from
13 recipients displaying early-onset dnDSAs (dark grey bars) and
17 recipients positive for late-onset dnDSAs (light grey bars). The
biopsy findings were analyzed both individually (i, t, ptc, g, ci, ct, cg,
cv, v) and in functional clusters (ptc + g referring tomicrocirculation
inflammation, ptc + g + cg to microcirculation lesions, i + t to
tubulointerstitial inflammation, and ci + ct to tubulointerstitial
scarring). Data are presented as the mean ± standard error. For each
parameter, no significant difference was observed between the two
groups.
relevance in view of the need to establish the optimal terms
of posttransplant DSA surveillance strategy, particularly con-
cerning monitoring length.
Our study, carried out in a homogeneous patient pop-
ulation not including sensitized recipients, demonstrates
that the time interval to AMR development and graft loss,
evaluated from the first dnDSA appearance, does not differ in
the early- and late-onset HLA-antibody groups. In previous
studies, it had been shown that DSAs developing within
the first year after transplantation resulted in early graft
failure, whereas late-onset DSAs, although also detrimental,
seemed to require a longer time to finally cause graft damage
and loss [7, 9]. These latter observations likely reflected the
presence of a proportion of sensitized patients, in whom
rapid development of DSA-mediated tissue damage could
have been sustained by the presence of a cytokine inflam-
matory milieu [28, 29] and further amplified by a parallel
action of non-DSAs specific for mismatched cross-reactive
epitopes [8]. In our cohort of pediatric recipients, a model
intrinsically free of relevant comorbidities, a thorough and
prolonged posttransplant antibody monitoring permitted an
accurate estimate of the interval between DSA onset and
graft function deterioration, thus allowing assessment of the
actual damaging potential of dnDSAs emerging in the late
posttransplant period. Through this longitudinal detection
approach, we demonstrated that DSAs in the two patient
groups displayed equivalent damaging capabilities. Indeed,
early- and late-onset dnDSAs did not differ in the biological
properties, such as highMFI values and complement-binding
ability, recently demonstrated to be the main determinants
of antibody-mediated graft damage and loss [26, 27, 30–
32]. In particular, all of the graft losses in both groups
were observed in patients displaying DSAs capable of C3d
binding, as a result of progressive acquisition over time of
C1q- and C3d-fixing ability, paralleled by an increase in MFI
values [27]. The size of our pediatric cohort, smaller than
average adult series, may have partly influenced our statistical
findings and limited our ability to dissect the respective role
of complement-binding activity and MFI on graft outcome.
While Lee et al. observed an earlier production of HLA
class I DSAs [7], we found that HLA class I and class II
dnDSAswere comparably represented in both early- and late-
onset groups. This apparent discrepancy could be in part
explained by the fact that our study exclusively analyzed
nonsensitized recipients. Indeed, in a first set alloresponse
condition, the ubiquitous cellular expression of class I HLA
antigens within the kidney graft tissue may be balanced by
the greater stimulating capability of the highly polymorphic
class II molecules, in particular HLA DQ antigens [11–15,
22]. Moreover, comparing C1q- and C3d-binding capabilities
in class I and class II dnDSAs, we demonstrated in both
patient groups that C3d binding was almost exclusively a
property of class II, whereas C1q binding was expressed
in a similar percentage by both classes. This finding gives
additional strength to previous data demonstrating that, in
nonsensitized low-risk kidney recipients, class II specific and,
in particular, anti-DQ de novo antibodies are the principal
effectors of graft loss in all posttransplant phases [11–15, 22,
27, 30]. The equivalency of early and late dnDSA damaging
capacity was further supported by the observation that the
two study groups displayed a similar histological pattern of
tissue graft damage. In this regard, it is worth underlining
that, in our cohort represented by recipients of grafts from
young donors, the susceptibility to HLA-antibody mediated
insult is only marginally influenced by organ ageing [33].
At present, the reasons for dnDSA production in some
patients and not in others, as well as the biological fac-
tors influencing their development at different times after
transplant, in the presence of the same degree of HLA
mismatching and the same immunosuppressive regimen, are
not completely understood. In this study, younger recipient
age appeared to favor an earlier dnDSA production, likely
reflecting a propensity to display a stronger alloreactivity,
that suggests a note of caution in immunosuppressive therapy
minimization in the pediatric setting.
5. Conclusions
Based on our findings, management of patients found pos-
itive for dnDSAs at late phases of posttransplant follow-up
should not differ from that applied in the early-onset dnDSA
patient group.
Thus, monitoring of HLA antibodies throughout the
entire posttransplant course is recommended, despite high
costs and organization difficulties, in order to identify
patients at risk for AMR and graft loss.
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